Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

2015 Was a Banner Year for Personalized Medicine, PhRMA Reports

1/27/2016

0 Comments

 
Washington DC — According to Pharmaceutical Research and Manufacturers of America (PhRMA), 2015 was a record year for personalized medicine approvals, according to a new analysis from the Personalized Medicine Coalition (PMC).
 
Writing on PhRMA’s blog The Catalyst, PhRMA’s Emma Van Hook reports that this news confirms the growing role of personalized medicine as an approach to treatment that can improve outcomes for patients and also create important efficiencies in the health care system.
 
Personalized medicine is an emerging field of medicine that uses diagnostic tools to identify specific biological markers to help assess which medical treatments and procedures will be best for each patient.  
​Personalized medicine also takes into account patients’ medical history, circumstances and values in developing targeted treatment and prevention plans.
 
In what has already been noted as a banner year for new medicines, with 45 novel new drugs approved in 2015, the new analysis indicates that 28 percent of novel new drugs approved by the Food and Drug Administration in 2015 were personalized, or precision, medicines.
 
This continued growth from the year before, where 21 percent of approvals were found to be personalized medicines, is reflective of the rapid progress we’re seeing in advancing targeted treatments for patients and affirms that personalized medicine has become an established approach to fighting a range of diseases.
 
Previously, there were just a handful approved each year.
 
“The new analysis today affirms the biopharmaceutical industry’s commitment to developing personalized medicines. The continual increase of approved targeted therapies indicates where the science, research and the industry are all heading,” noted Edward Abrahams, president of PMC.
 
In recent years, we’ve seen tremendous advances in targeted therapies for diseases like cystic fibrosis, hepatitis C and many other conditions.  But, without a doubt, we’ve seen the greatest transformation in oncology.
 
A growing understanding of the molecular underpinnings of what was once referred to as a singular disease is enabling targeted therapeutic approaches for many forms of cancer. In 2015, 35 percent of new cancer medicines were found to be personalized medicines.
 
Some of the personalized medicine highlights from 2015 include:
 
  • Two new medicines for patients with different forms of non-small cell lung cancer;
  • A new combination therapy for patients with cystic fibrosis;
  • Two new medicines to help patients with a difficult-to-treat form of high cholesterol; and
  • A new targeted therapy for melanoma.
 
America’s biopharmaceutical companies have long been committed to accelerating the development of personalized medicines.  The pipeline has never been more promising, with more than 40 percent of compounds in development having the potential to be personalized medicines.
 
In cancer, that number is ever greater with 73 percent of cancer medicines in the pipeline potentially personalized.
 
The era of targeted therapy is rapidly transforming care for patients; we’re eager to see what 2016 will bring.
 
To learn more about the biopharmaceutical industry’s commitment to discovering new treatments and cures for cancer, visit www.fromhopetocures.org/cancer and www.innovation.org.
 
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.  Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507